LYNDRA THERAPEUTICS
REINVENTING MEDICINES FOR A HEALTHIER WORLD
team
Board of Directors
Company advisors
Company Timeline
Founded on technology developed within the MIT lab of Dr. Robert Langer in collaboration with the Bill & Melinda Gates Foundation
Platform and single agent preclinical in 2 species
($0.3 M NIH Grant)
Demonstrated gastric residence achievable with desired pharmacokinetics-single agent
($23 M Series A, $105 M AbbVie Partnership, $6 M NIH Grant(s), $4 M BMGF Grant)
Demonstrated once-weekly dosage form can safely reside in the stomach with predictable pharmacokinetics – single agent
($18 M NIH Grant(s), $13 M BMGF Grant)
Demonstrated once-weekly dosage form can safely reside in the stomach with predictable pharmacokinetics – two agents in one capsule and preliminary food effects
($60 M Series B, $122 M Gilead Partnership, $19M NIH Grant, $3 M DoD Grant)
Expanded pipeline, repeat dosing, and food effects
($2M BMGF Grant, $1M NIH Grant)
Founded on technology developed within the MIT lab of Dr. Robert Langer in collaboration with the Bill & Melinda Gates Foundation
investors & partners
























Previous
Next